Related references
Note: Only part of the references are listed.Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Laura K. Schmalbrock et al.
BLOOD (2021)
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
Nikhil Patkar et al.
LEUKEMIA (2021)
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
Simona Soverini et al.
BLOOD (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph plus ALL
Nicholas J. Short et al.
BLOOD CANCER JOURNAL (2020)
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Travers Ching et al.
BMC CANCER (2020)
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study
Pierre-Jean Lamy et al.
CANCERS (2020)
Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study
Lori S. Muffly et al.
BLOOD (2020)
Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial
Othman Al-Sawaf et al.
BLOOD (2020)
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
Daniela Drandi et al.
HEMASPHERE (2020)
getITD for FLT3-ITD-based MRD monitoring in AML
Tamara J. Blaette et al.
LEUKEMIA (2019)
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
Aytug Kizilors et al.
LANCET HAEMATOLOGY (2019)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine
Scott R. Daigle et al.
BLOOD (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay
Christopher Wai Siong Ng et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory
Piers Blombery et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
Somatic mutations precede myeloid leukemia years before diagnosis
Pinkal Desai et al.
NATURE MEDICINE (2018)
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
Jesse J. Salk et al.
NATURE REVIEWS GENETICS (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret et al.
HAEMATOLOGICA (2018)
IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Lucie Petrova et al.
CLINICAL BIOCHEMISTRY (2018)
Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias
Michael W. Schmitt et al.
CLINICAL CANCER RESEARCH (2018)
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL
Brent Wood et al.
BLOOD (2018)
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
Mark J. Levis et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
Adam Waalkes et al.
HAEMATOLOGICA (2017)
Biological and clinical consequences of NPM1 mutations in AML
E. M. Heath et al.
LEUKEMIA (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status
Chiara Pesenti et al.
ONCOTARGET (2017)
Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
Adam Waalkes et al.
HAEMATOLOGICA (2017)
Incorporation of unique molecular identifiers in TruSeq adapters improves the accuracy of quantitative sequencing
Jungeui Hong et al.
BIOTECHNIQUES (2017)
Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma
Marzia Cavalli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients
Olga Sala Torra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
Wendy T. Parker et al.
BLOOD (2016)
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
Christine E. Ryan et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia
Irene Della Starza et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry
Michael J. Mosko et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Coming of age: ten years of next-generation sequencing technologies
Sara Goodwin et al.
NATURE REVIEWS GENETICS (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeted therapies in CLL: mechanisms of resistance and strategies for management
Jennifer A. Woyach et al.
BLOOD (2015)
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma A Comparison with Real-Time PCR
Daniela Drandi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Sequencing small genomic targets with high efficiency and extreme accuracy
Michael W. Schmitt et al.
NATURE METHODS (2015)
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
Houria Debarri et al.
ONCOTARGET (2015)
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
A. Kohlmann et al.
LEUKEMIA (2014)
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Simona Soverini et al.
LEUKEMIA RESEARCH (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
W. T. Parker et al.
BRITISH JOURNAL OF CANCER (2013)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Absolute quantification by droplet digital PCR versus analog real-time PCR
Christopher M. Hindson et al.
NATURE METHODS (2013)
Using synthetic templates to design an unbiased multiplex PCR assay
Christopher S. Carlson et al.
NATURE COMMUNICATIONS (2013)
Brief report Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
Wendy T. Parker et al.
BLOOD (2012)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R. Loken et al.
BLOOD (2012)
Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
Hiroto Inaba et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Sebastian Boettcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Counting absolute numbers of molecules using unique molecular identifiers
Teemu Kivioja et al.
NATURE METHODS (2012)
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation
Alexandra S. Whale et al.
NUCLEIC ACIDS RESEARCH (2012)
Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy
Wendy T. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Microfluidic stochastic confinement enhances analysis of rare cells by isolating cells and creating high density environments for control of diffusible signals
Meghan E. Vincent et al.
CHEMICAL SOCIETY REVIEWS (2010)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P. Hughes et al.
BLOOD (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia
T. Flohr et al.
LEUKEMIA (2008)
Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer
Ali Bashir et al.
PLOS COMPUTATIONAL BIOLOGY (2008)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry
Pratip K. Chattopadhyay et al.
NATURE MEDICINE (2006)
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
Jaspal Kaeda et al.
BLOOD (2006)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection
AH Li et al.
BLOOD (2003)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia
L Wang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Share Paper
